Cargando…
Alirocumab in Post ACS Patients - Saving Lives at a Premium
Autores principales: | George, Melvin, Goenka, Luxitaa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241115/ https://www.ncbi.nlm.nih.gov/pubmed/34082687 http://dx.doi.org/10.2174/1573403X17666210603111158 |
Ejemplares similares
-
The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic
Nephropathy
por: Goenka, Luxitaa, et al.
Publicado: (2019) -
The assessment of the quality of randomized controlled trials published in Indian medical journals
por: Goenka, Luxitaa, et al.
Publicado: (2019) -
Mortality Benefit of Alirocumab: A Bayesian Perspective
por: Labos, Christopher, et al.
Publicado: (2019) -
Avaliação da Senescência de Células Sanguíneas Mononucleares Periféricas e na Disfunção Endotelial entre Adultos com Alto Risco Cardiovascular
por: Raj, Vijay, et al.
Publicado: (2021) -
Premium Teeth
Publicado: (1850)